California Judge Limits Expert Testimonies in Biogen and Genentech Patent Royalty Trial

A California federal judge has set the guidelines for the impending jury trial involving Biogen and Genentech, a subsidiary of Roche Holding AG. The dispute revolves around patent royalties tied to the sales of multiple sclerosis drugs. The judge has allotted nine hours for each party to present their cases and has announced her intention to restrict the number of expert testimonies. This measure is expected to streamline the proceedings and focus the arguments presented to the jury. For further details on the case parameters, visit the original Law360 article.